Info

Topotarget A/S is a Denmark-based provider of healthcare solutions. The Company's activities cover most aspects of drug development, including assay development, screening, biology, medicinal chemistry, preclinical and clinical trials, regulatory affairs, marketing, licensing and sales. There are two primary areas of development: specialty oncology products, which are marketed by a specialized sales force in Europe, and product candidates with potential broad cancer applications. Some of the Company's partners are CuraGen, active in the research, development and commercialization of HDAC inhibitors in all human diseases; The United States National Cancer Institute, which sponsors clinical trials on PXD101 and also conduct preclinical research on other HDAC inhibitors, and Inhibox, a provider of computational capability in the area of virtual screening for lead identification in its preclinical projects. Topotarget has operations in Denmark, the United Kingdom and Germany.